Rheumatoid arthritis diagnostic tests help to determine the level of inflammation and diagnose the condition in patients experiencing joint pain and stiffness. Tests like serum rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and erythrocyte sedimentation rate (ESR) are commonly used to diagnose rheumatoid arthritis. Advancements in diagnostic technologies have enabled quicker and accurate diagnosis of rheumatoid arthritis. The global Rheumatoid Arthritis Diagnostic Tests Market is estimated to be valued at US$ 625.22 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancement in diagnostic technologies is one of the key trends driving the growth of the rheumatoid arthritis diagnostic tests market. Utilization of advanced methods like ultrasonography, MRI, and CT scans has improved the way rheumatoid arthritis is diagnosed. MRI scans help detect inflammatory changes in joints before erosions are visible on regular X-rays. This enables early diagnosis and treatment of rheumatoid arthritis. Development of novel biomarker tests is also spurring market growth. Companies are focusing on development of multi-marker diagnostic panels and tests based on proteomics and metabolomics approaches to facilitate quick and accurate diagnosis of rheumatoid arthritis.
Segment Analysis
The global rheumatoid arthritis diagnostic tests market is dominated by serology tests segment. Serology tests detect the presence of antibodies or proteins in the blood that are associated with inflammation and joint damage. These includes tests like rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody tests. Serology tests are preferred initially by healthcare professionals for rheumatoid arthritis diagnosis due to their high sensitivity and specificity.
Key Takeaways
The global rheumatoid arthritis diagnostic tests market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis shows that North America region currently dominates the market and is expected to continue its dominance in coming years. Factors such as increasing prevalence of rheumatoid arthritis, growing geriatric population, and rising healthcare expenditure are fueling the growth of rheumatoid arthritis diagnostic tests market in the region.
Key players operating in the rheumatoid arthritis diagnostic tests market include Abbott Laboratories, F. Hoffmann-La Roche AG, QIAGEN, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Euro Diagnostica AB, anti-CCP test by Trinity Biotech Plc. Abbott Laboratories and Roche Diagnostics currently hold a sizable share in the global market due to their well-established product portfolio and widespread geographic presence. Bio-Rad Laboratories and QIAGEN are other prominent players focusing on new product launches and geographical expansion to consolidate their market position.
No comments:
Post a Comment